Abstract Background Psychogenic non-epileptic seizures (PNES) resemble epileptic seizures and are often misdiagnosed as epilepsy. Objective To investigate the frequency of PNES and to calculate the economic burden of the patients who admitted to video-electroencephalographicmonitoring (VEM) to obtain a diagnosis of epilepsy in order to apply for disability retirement. Methods The present retrospective study included 134 patients who required disability reports between 2013 and 2019 and had their definite diagnoses after VEM. Following VEM, the patients were divided into three groups: epilepsy, PNES, and epilepsy + PNES. Results In total, 22.4% (n = 30) of the patients were diagnosed with PNES, 21.6% (n = 29) with PNES and epilepsy, and 56% (n = 75), with epilepsy. The frequency of PNES among all patients was of 44% (n = 59). In patients with PNES alone, the annual cost of using anti-seizure medication was of 160.67 ± 94.04 dollars; for psychostimulant drugs, it was of 148.3 ± 72.48 dollars a year; and the mean direct cost for diagnostic procedures was of 582.9 ± 330.0 (range: 103.52–1601.3) dollars. Conclusions Although it is challenging to determine the qualitative and quantitative total cost in these patient groups, early diagnosis and sociopsychological support will reduce the additional financial burden on the health system and increase the quality of life of the patients. nonepileptic non (PNES videoelectroencephalographicmonitoring video electroencephalographicmonitoring VEM (VEM retirement 13 201 groups 224 22 4 22.4 n 30 216 21 6 21.6 29 56 75, 75 , 75) 44 59. 59 . 59) alone antiseizure anti seizure 16067 160 67 160.6 9404 94 04 94.0 drugs 1483 148 3 148. 7248 72 48 72.4 year 5829 582 9 582. 3300 330 0 330. range (range 103.52–1601.3 1035216013 103 52 1601 1 20 2 22. 21. 5 7 1606 16 160. 940 94. 14 724 72. 58 33 103.52–1601. 103521601 10 103.52–1601 10352160 103.52–160 1035216 103.52–16 103521 103.52–1 10352 103.52– 1035 103.52 103.5 103.
Resumo Antecedentes As crises psicogênicas não epilépticas (CPNE) se assemelham a crises epilépticas, e muitas vezes são diagnosticadas erroneamente como epilepsia. Objetivo Investigar a frequência de CPNE e calcular o impacto econômico dos pacientes internados para serem submetidos a monitoramento videoencefalográfico (MVE) para obter um diagnóstico de epilepsia e requerer aposentadoria por invalidez. Métodos Este estudo retrospectivo incluiu 134 pacientes que solicitaram laudo médico de incapacidade entre 2013 e 2019, e obtiveram seus diagnósticos definitivos após serem submetidos a MEV. Os pacientes foram divididos em três grupos: epilepsia, CPNE, e epilepsia + CPNE. Resultados Após o MEV, 22,4% (n = 30) dos pacientes foram diagnosticados com CPNE, 21,6% (n = 29), com CPNE + epilepsia, e 56%, com epilepsia. A frequência de CPNE entre todos os pacientes foi de 44% (n = 59). Em pacientes somente com CPNE, o custo anual do uso de anticonvulsivantes foi de US$ 160,67 ± 94,04; para os psicoestimulantes, o custo anual foi de US$ 148,3 ± 72,48; e a média do custo direto de procedimentos diagnósticos foi de US$ 582,9 ± 330,0 (variação: 103,52–1601,3). Conclusões Embora seja um desafio determinar o custo total qualitativo e quantitativo nesses grupos de pacientes, o diagnóstico precoce e o apoio sociopsicológico reduzirão o impacto financeiro adicional ao sistema de saúde e aumentarão a qualidade de vida dos pacientes. (CPNE MVE (MVE invalidez 13 201 2019 MEV 224 22 4 22,4 n 30 216 21 6 21,6 29, 29 , 29) 56 56% 44 59. 59 . 59) US 16067 160 67 160,6 94,04 9404 94 04 psicoestimulantes 1483 148 3 148, 72,48 7248 72 48 5829 582 9 582, 3300 330 0 330, variação (variação 103,52–1601,3. 1035216013 103,52–1601,3 103 52 1601 103,52–1601,3) 1 20 2 22, 21, 5 1606 16 160, 94,0 940 14 72,4 724 7 58 33 103521601 103,52–1601, 10 94, 72, 10352160 103,52–1601 1035216 103,52–160 103521 103,52–16 10352 103,52–1 1035 103,52– 103,52 103,5 103,